Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
Abstract GSK3640254 (GSK'254) is a novel HIV‐1 maturation inhibitor with pharmacokinetics supporting once‐daily (QD) therapy for HIV‐1 treatment. This thorough QT/corrected QT (QTc) study evaluated the effect of GSK'254 on cardiac repolarization. In this two‐part, randomized study, healthy...
Saved in:
Main Authors: | Ying Zhang (Author), Mark Bush (Author), Parto Yazdani (Author), Joyce Zhan (Author), Bo Wen (Author), Veronica Bainbridge (Author), Brian R. Wynne (Author), Samit Joshi (Author), Max Lataillade (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
by: Samit R. Joshi, et al.
Published: (2020) -
Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254)
by: Konstantinos Stamatopoulos, et al.
Published: (2023) -
Effect of QT interval-prolonging drugs taken in pregnancy on the neonatal QT interval
by: Holger Michel, et al.
Published: (2023) -
A phase I, first‐in‐human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937
by: Paul D. Benn, et al.
Published: (2023) -
Abemaciclib does not increase the corrected QT interval in healthy participants
by: Jill C. Chappell, et al.
Published: (2023)